Spain plants US$200m flag in Boston with debut US biotech fund

The move marks the first time Spain has seeded a US-based venture fund with public capital, deploying around US$57m of taxpayer money to back both Spanish start-ups as they integrate and scale in Boston and select US biotechs aligned with Madrid’s strategic priorities.

The Spain–Boston Biotechnology initiative was unveiled by Deputy Prime Minister and Economy Minister Carlos Cuerpo at the Spain-US Business Summit in Boston on 14 April 2026. Spain will open a new trade office in Massachusetts to run alongside the fund, its eighth commercial office in the United States.

“We see this initiative as a unique opportunity to make the most of existing complementarities and build bridges between our two ecosystems,” Cuerpo said in his announcement. “We will be supporting the integration and scaling of high-potential Spanish life sciences companies within the Boston ecosystem, seeking to contribute to innovation, job creation and, of course, long-term bilateral economic development. And at the same time, we hope to bring our pioneering research and clinical trial activity to medical infrastructure and American firms in Boston, generating opportunities for joint research, co-investment and also reinforcing the alignment between science and industrial development”.

The fund targets a well-documented gap in Spain’s otherwise fast-rising life sciences sector. Spain has emerged as a European hub for R&D, but it still lacks the venture capital and commercialisation infrastructure needed to turn scientific breakthroughs into global blockbuster drugs. By embedding capital directly in Boston, Madrid aims to give Spanish founders a fast pass into the network of investors and business-development teams that define the US biotech scene.

Crucially, the fund’s dual strategy is meant to help Spanish biotechs grow in Boston and become world-leading companies while keeping intellectual property in Spain.

For Europe’s biotech scene, the move is a pragmatic admission that geography still matters and that the centre of gravity for commercialisation remains heavily US-centric. It also raises a familiar tension: Will the fund achieve its goal of acting as a bridge, allowing Spanish founders to scale globally and reinvest back home? Or will it accelerate the brain drain of talent and IP to the United States? Either way, Spain’s decision to anchor its biotech ambition in Boston rather than at home signals that, at least for now, the fastest route to a European life sciences champion may run through Massachusetts.